AES-350

• Description :

  AES-350 is a potent and orally active HDAC6 inhibitor with an IC50 and a Ki of 0.0244 μM and 0.035 μM, respectively. AES-350 is also against HDAC3, HDAC8 in an enzymatic activity assay with IC50 values of 0.187 μM and 0.245 μM, respectively. AES-350 triggers apoptosis in AML cells through HDAC inhibition and can be used for acute myeloid leukemia (AML) research[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H228, H315, H319

• Target :

  Apoptosis; HDAC

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/aes-350.html

• Purity :

  99.30

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(NO)C1=CC=C(NC(C2=CC=C(C(C)(C)C)C=C2)=O)C=C1

• Molecular Formula :

  C18H20N2O3

• Molecular Weight :

  312.36

• Precautions :

  H228, H315, H319

• References & Citations :

  [1]Andrew E Shouksmith, et al. Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HDAC11; HDAC3; HDAC6

• CAS Number :

  [847249-57-4]